Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

We describe the outcome of the Biomarkers Consortium CSF Proteomics Project (where CSF is cerebral spinal fluid), a public–private partnership of government, academia, nonprofit, and industry. The goal of this study was to evaluate a multiplexed MS‐based approach for the qualification of candidate Alzheimer's disease (AD) biomarkers using CSF samples from the AD Neuroimaging Initiative.

[1]  H. Inada,et al.  Fatty acid binding proteins and the nervous system: Their impact on mental conditions , 2016, Neuroscience Research.

[2]  M. Rowe,et al.  Depression in informal caregivers of persons with dementia. , 2015, International journal of older people nursing.

[3]  Y. Iwayama,et al.  Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies , 2014, Human molecular genetics.

[4]  E. Beattie,et al.  An Exploratory Study of Grief and Health-Related Quality of Life for Caregivers of People With Dementia , 2014, American journal of Alzheimer's disease and other dementias.

[5]  E. Diamandis,et al.  Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls , 2014, Acta Neuropathologica.

[6]  S. Engelborghs,et al.  Biobanking of CSF: international standardization to optimize biomarker development. , 2014, Clinical biochemistry.

[7]  Pei Wang,et al.  Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins , 2013, Nature Methods.

[8]  O. Andreassen,et al.  Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration , 2013, Molecular Neurodegeneration.

[9]  William A Banks,et al.  Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  S. Carr,et al.  Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.

[11]  A. Fagan,et al.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. , 2012, Biomarkers in medicine.

[12]  A. Fagan,et al.  Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. , 2012, Human molecular genetics.

[13]  C. Borchers,et al.  Comparison of standard- and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins , 2012, Analytical and Bioanalytical Chemistry.

[14]  L. Blum,et al.  Recent advances in multiplex immunoassays. , 2012, Bioanalysis.

[15]  L. McDonnell,et al.  A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid. , 2012, Methods.

[16]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[17]  H. Mischak,et al.  Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers , 2011, PloS one.

[18]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Cancer.

[19]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[20]  D. Petersen,et al.  The human fatty acid-binding protein family: Evolutionary divergences and functions , 2011, Human Genomics.

[21]  Sanjeeva Srivastava,et al.  Protein microarrays and novel detection platforms , 2011, Expert review of proteomics.

[22]  S. Grebe,et al.  LC-MS/MS in the Clinical Laboratory - Where to From Here? , 2011, The Clinical biochemist. Reviews.

[23]  Ge Li,et al.  Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease , 2011, PloS one.

[24]  R. Brookmeyer,et al.  National estimates of the prevalence of Alzheimer’s disease in the United States , 2011, Alzheimer's & Dementia.

[25]  P. Bongioanni,et al.  Distribution of VGF peptides in the human cortex and their selective changes in Parkinson’s and Alzheimer’s diseases , 2010, Journal of anatomy.

[26]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[27]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, PloS one.

[28]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[29]  Matthew C Wiener,et al.  Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry. , 2010, Journal of proteome research.

[30]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[31]  Nelleke Tolboom,et al.  Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding , 2009, Journal of Nuclear Medicine.

[32]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[33]  A. Drzezga,et al.  Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.

[34]  A. Fagan,et al.  Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. , 2009, Archives of neurology.

[35]  K. Blennow,et al.  Rapid Progression from Mild Cognitive Impairment to Alzheimer’s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the APOE ε4/ε4 Genotype , 2009, Dementia and Geriatric Cognitive Disorders.

[36]  R. Aebersold,et al.  Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.

[37]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[38]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[39]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[40]  Gunhild Waldemar,et al.  Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. , 2007, Archives of neurology.

[41]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[42]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[43]  Pieter Visser,et al.  Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. , 2006 .

[44]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[45]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[46]  R. Possenti,et al.  Processing, Distribution, and Function of VGF, a Neuronal and Endocrine Peptide Precursor , 2004, Cellular and Molecular Neurobiology.

[47]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[48]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[49]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[50]  M. J. Wade,et al.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.

[51]  J. Li,et al.  Comparison of VGF and trk mRNA distributions in the developing and adult rat nervous systems. , 1997, Brain research. Molecular brain research.

[52]  K M Heilman,et al.  Atrophy of the hippocampus, parietal cortex, and insula in Alzheimer's disease: a volumetric magnetic resonance imaging study. , 1997, Neuropsychiatry, neuropsychology, and behavioral neurology.

[53]  R. Yost,et al.  Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation. , 1979, Analytical chemistry.

[54]  A. Lawson.  The scope of mass spectrometry in clinical chemistry. , 1975, Clinical chemistry.

[55]  Tim Schultz,et al.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. , 2013, British journal of clinical pharmacology.

[56]  G. Schellenberg,et al.  CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. , 2007, Neurology.

[57]  T. Speed,et al.  Statistical issues in cDNA microarray data analysis. , 2003, Methods in molecular biology.

[58]  R. Holsinger,et al.  Neurotrophic factors and Alzheimer's disease: are we focusing on the wrong molecule? , 2002, Journal of neural transmission. Supplementum.

[59]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[60]  P. Lewi,et al.  Spectral mapping, a technique for classifying biological activity profiles of chemical compounds. , 1976, Arzneimittel-Forschung.

[61]  Lewi Pj,et al.  Spectral mapping, a technique for classifying biological activity profiles of chemical compounds. , 1976 .

[62]  Edu,et al.  Molecular Neurodegeneration Apolipoprotein E Levels in Cerebrospinal Fluid and the Effects of Abca1 Polymorphisms , 2022 .